Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 9/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2E1 | P05181 | 3/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.42 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27483841 | 0.86 | HDAC1 (0.51) | HDAC1HDAC6CYP2A6ALDH1A1LMNA | |
| SCHEMBL12369723 | 0.84 | HDAC1 (0.54) | HDAC1HDAC6CYP2A6ALDH1A1LMNA | |
| SCHEMBL12395816 | 0.81 | HDAC1 (0.52) | HDAC1HDAC6CYP2A6ALDH1A1LMNA | |
| SCHEMBL5015554 | 0.81 | HDAC1 (0.55) | HDAC1HDAC6CYP2A6ALDH1A1LMNA | |
| SCHEMBL2641155 | 0.81 | HDAC1 (0.52) | HDAC1HDAC6CYP2A6ALDH1A1LMNA | |
| SCHEMBL5015510 | 0.81 | HDAC1 (0.55) | HDAC1HDAC6CYP2A6ALDH1A1LMNA | |
| SCHEMBL2641158 | 0.81 | HDAC1 (0.52) | HDAC1HDAC6CYP2A6ALDH1A1LMNA | |
| SCHEMBL6421317 | 0.79 | HDAC1 (0.50) | HDAC1HDAC6CYP2A6ALDH1A1LMNA | |
| SCHEMBL14086708 | 0.78 | HDAC1 (0.49) | HDAC1HDAC6CYP2A6ALDH1A1LMNA | |
| SCHEMBL6421312 | 0.78 | HDAC1 (0.49) | HDAC1HDAC6CYP2A6ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100509833-C | Macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG (CH) | 2009-07-08 | — | — | CN | claimed |
| CN-1630661-A | Macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG (CH) | 2005-06-22 | — | — | CN | claimed |
| US-20040220120-A1 | Novel anhydrolide derivatives having antibacterial activity | VO NHA HUU (US) | 2004-11-04 | — | — | US | claimed |
| WO-2004069854-A1 | NOVEL ANHYDROLIDE DERIVATIVES HAVING ANTIBACTERIAL ACTIVITY | ENANTA PHARMACEUTICALS. INC. (US) | 2004-08-19 | — | — | WO | claimed |
| US-6720308-B1 | Anhydrolide derivatives having antibacterial activity | ENANTA PHARMACEUTICALS, INC. | 2004-04-13 | — | — | US | claimed |
| CN-101289483-B | Macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG | 2012-06-20 | — | — | CN | disclosed |
| CN-101367854-B | Macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG | 2010-12-29 | — | — | CN | disclosed |
| CN-100509833-C | Macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG (CH) | 2009-07-08 | — | — | CN | disclosed |
| CN-101367854-A | Macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG (CH) | 2009-02-18 | — | — | CN | disclosed |
| CN-101289484-A | Macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG (CH) | 2008-10-22 | — | — | CN | disclosed |
| CN-101289483-A | Macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG (CH) | 2008-10-22 | — | — | CN | disclosed |
| CN-1234718-C | New macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG (CH) | 2006-01-04 | — | — | CN | disclosed |
| CN-1630661-A | Macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG (CH) | 2005-06-22 | — | — | CN | disclosed |
| US-20040220120-A1 | Novel anhydrolide derivatives having antibacterial activity | VO NHA HUU (US) | 2004-11-04 | — | — | US | disclosed |
| WO-2004069854-A1 | NOVEL ANHYDROLIDE DERIVATIVES HAVING ANTIBACTERIAL ACTIVITY | ENANTA PHARMACEUTICALS. INC. (US) | 2004-08-19 | — | — | WO | disclosed |
| US-6720308-B1 | Anhydrolide derivatives having antibacterial activity | ENANTA PHARMACEUTICALS, INC. | 2004-04-13 | — | — | US | disclosed |
| CN-1464880-A | New macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG (CH) | 2003-12-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220120-A1 | Novel anhydrolide derivatives having antibacterial activity | GALE, GNE, GMDS | HDAC1 1232/4885HDAC6 171/4885CYP2A6 1059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.